Xience implantation followed by short dual antiplatelet therapy: ‘the new normal’?

Niels M.R. van der Sangen; Wouter J. Kikkert; José P.S. Henriques; Bimmer E.P.M. Claessen

Xience implantation followed by short dual antiplatelet therapy: ‘the new normal’?

Niels M.R. van der Sangen
, Wouter J. Kikkert
, José P.S. Henriques
, Bimmer E.P.M. Claessen

Research output: Contribution to journal › Editorial

Abstract

The XIENCE family of everolimus-eluting stents ranks among the most used and most widely studied drug-eluting stents worldwide. In patients at high bleeding risk undergoing non-complex percutaneous coronary intervention with these stents, a shortened dual antiplatelet therapy (DAPT) regimen of 1–3 months appears to be associated with a reduced rate of major bleeding, a similar rate of ischaemic events and a very low incidence of stent thrombosis after DAPT discontinuation compared with DAPT up to 12 months.

Original language	English
Pages (from-to)	1-2
Number of pages	2
Journal	Heart International
Volume	15
Issue number	2
State	Published - 2021
Externally published	Yes

Keywords

Aspirin
Drug-eluting stents
Dual anti-platelet therapy
High bleeding risk
P2Y12 inhibitor
Percutaneous coronary intervention
XIENCE stent

Cite this

@article{3986c97e4bfc4482b4807d57a49c7fb1,

title = "Xience implantation followed by short dual antiplatelet therapy: {\textquoteleft}the new normal{\textquoteright}?",

abstract = "The XIENCE family of everolimus-eluting stents ranks among the most used and most widely studied drug-eluting stents worldwide. In patients at high bleeding risk undergoing non-complex percutaneous coronary intervention with these stents, a shortened dual antiplatelet therapy (DAPT) regimen of 1–3 months appears to be associated with a reduced rate of major bleeding, a similar rate of ischaemic events and a very low incidence of stent thrombosis after DAPT discontinuation compared with DAPT up to 12 months.",

keywords = "Aspirin, Drug-eluting stents, Dual anti-platelet therapy, High bleeding risk, P2Y12 inhibitor, Percutaneous coronary intervention, XIENCE stent",

author = "\{van der Sangen\}, \{Niels M.R.\} and Kikkert, \{Wouter J.\} and Henriques, \{Jos{\'e} P.S.\} and Claessen, \{Bimmer E.P.M.\}",

year = "2021",

language = "English",

volume = "15",

pages = "1--2",

journal = "Heart International",

issn = "1826-1868",

publisher = "Touch Medical Media",

number = "2",

}

TY - JOUR

T1 - Xience implantation followed by short dual antiplatelet therapy

T2 - ‘the new normal’?

AU - van der Sangen, Niels M.R.

AU - Kikkert, Wouter J.

AU - Henriques, José P.S.

AU - Claessen, Bimmer E.P.M.

PY - 2021

Y1 - 2021

N2 - The XIENCE family of everolimus-eluting stents ranks among the most used and most widely studied drug-eluting stents worldwide. In patients at high bleeding risk undergoing non-complex percutaneous coronary intervention with these stents, a shortened dual antiplatelet therapy (DAPT) regimen of 1–3 months appears to be associated with a reduced rate of major bleeding, a similar rate of ischaemic events and a very low incidence of stent thrombosis after DAPT discontinuation compared with DAPT up to 12 months.

AB - The XIENCE family of everolimus-eluting stents ranks among the most used and most widely studied drug-eluting stents worldwide. In patients at high bleeding risk undergoing non-complex percutaneous coronary intervention with these stents, a shortened dual antiplatelet therapy (DAPT) regimen of 1–3 months appears to be associated with a reduced rate of major bleeding, a similar rate of ischaemic events and a very low incidence of stent thrombosis after DAPT discontinuation compared with DAPT up to 12 months.

KW - Aspirin

KW - Drug-eluting stents

KW - Dual anti-platelet therapy

KW - High bleeding risk

KW - P2Y12 inhibitor

KW - Percutaneous coronary intervention

KW - XIENCE stent

UR - https://www.scopus.com/pages/publications/85121260832

M3 - Editorial

AN - SCOPUS:85121260832

SN - 1826-1868

VL - 15

SP - 1

EP - 2

JO - Heart International

JF - Heart International

IS - 2

ER -

Xience implantation followed by short dual antiplatelet therapy: ‘the new normal’?

Abstract

Keywords

Fingerprint

Cite this